Subunit vaccine based on glycoprotein B protects pattern animal guinea pigs from tissue damage caused by infectious bovine rhinotracheitis virus

• Published in: Virus research Vol. 320; p. 198899
• Main Authors: Hou, Li-na, Wang, Feng-xue, Wang, Ya-xin, Guo, Hao, Liu, Chun-yu, Zhao, Hong-zhe, Yu, Ming-hua, Wen, Yong-jun
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 15.10.2022
• Subjects: Animals; antibodies; Antibodies, Neutralizing; Antibodies, Viral; Bovine alphaherpesvirus 1; Bovine herpesvirus type 1; Cattle; cattle industry; genes; genetic vectors; Glycoprotein B; glycoproteins; Guinea Pigs; Herpesvirus 1, Bovine - genetics; histopathology; immunity; Infectious bovine rhinotracheitis; Infectious Bovine Rhinotracheitis - prevention & control; lungs; Prokaryotic expression; protective effect; secretion; Subunit vaccine; subunit vaccines; vaccination; Vaccines, Inactivated; Vaccines, Subunit - genetics; viral load; Viral Vaccines - genetics; viruses; Glycoprotein B; Infectious bovine rhinotracheitis; Prokaryotic expression; Subunit vaccine; Guinea pigs; Bovine herpesvirus type 1
• ISSN: 0168-1702; 1872-7492; 1872-7492
• DOI: 10.1016/j.virusres.2022.198899

•We obtained a BoHV-1 glycoprotein B subunit vaccine by prokaryotic expression.•BoHV-1 can successfully infect the guinea pigs model.•The immunological characteristics of gB subunit vaccine was investigated in guinea pigs model.•IBRV gB subunit vaccine protects pattern animal guinea pigs from tissue damage caused by infectious bovine rhinotracheitis virus (BoHV-1). Infectious bovine rhinotracheitis (IBR) is caused by Bovine herpesvirus type 1 (BoHV-1), which seriously threatens the global cattle industry. Only vaccination to improve immunity is the most direct and effective means to prevent IBR. Attempts are being made to use subunit vaccines, deleted or recombinant viral vaccines to reduce or eradicate IBR. For investigating the immunological characteristics of glycoprotein B subunit vaccine in pattern animal guinea pigs, the partial glycoprotein B (gB) of BoHV-1 with dominant antigenic characteristic was selected. A recombinant prokaryotic expression vector pET-32a-gB with the truncated gB gene was constructed, expressed, identified and the purified proteins were used to immunize guinea pigs. The immune effect of the subunit vaccine was assessed by monitoring clinical symptoms, viral load, antibody secretion, and histopathological changes. The results indicated that guinea pigs immunized with the gB subunit vaccine produced high levels of anti-gB antibodies and virus-neutralizing antibodies. The gB subunit vaccine significantly reduced viral shedding and lung tissue damage after IBRV challenge. The animals inoculated the gB subunit vaccine also had less virus reactivation. Its protective effect on viral shedding and tissue damage was similar to that of inactivated BoHV-1 vaccine. This work is a proof-of-concept study of subunit vaccine-induced protection against BoHV-1. And it is expected to be a candidate vaccine for the prevention of IBR.